Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup or three of stimulation. Remember that no prescription is required, which means you need not worry about rebates. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch. …

The Centers for Medicare and Medicaid Services will slightly increase coverage for CAR-T therapies administered at certain large hospitals, and is considering other ways to pay more for the treatments, Reuters writes. CMS issued a proposed rule raising its maximum payment from 50% of estimated costs to 65%, which would increase reimbursement to $242,450 from the current $186,500. But that is still far short of actual costs. Gilead Sciences (GILD) and Novartis (NVS) charge $373,000 for advanced lymphoma, and Kymriah costs $475,000 for a type of pediatric leukemia.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy